Moreover, genomic variants that were found to be predictive of anti-EGFR resistance [23] in other tumour types are infrequent in TNBC patients [6, 24, 25] (Additional File 1: Fig. S1H), suggesting that non-genomic mechanisms of resistance must be at play in TNBCs. This evidence concerns the gene EGFR and neoplasm.